Breaking News

Virgin America Files for Proposed IPO to Raise $115 Million
Tweet TWEET

Medical Diagnostics Company STAT-Diagnostica Secures 22.1 Million USD/17 Million Euros in Series B Financing

  Medical Diagnostics Company STAT-Diagnostica Secures 22.1 Million USD/17
  Million Euros in Series B Financing

Business Wire

BARCELONA -- May 06, 2013

STAT-Diagnostica has announced the closing of a Series B financing round
totaling 22.1 million USD/17 million Euros, the proceeds of which will be used
to complete development of the company’s Near Patient Testing diagnostic
system and clinical validation of its first products. Led by new investor
Kurma Life Sciences Partners, the round also drew participation from new
investors Idinvest; Boehringer Ingelheim Venture Fund; and, Caixa Capital
Risc, the venture capital division of “la Caixa;” as well as existing
investors Ysios Capital and Axis.

Founded in 2010 and based in the Barcelona Science Park, STAT-Diagnostica
develops Near Patient Testing systems that simplify and reduce time to results
for the diagnosis of certain medical conditions. The company’s novel in vitro
diagnostic system is a versatile, easy-to-use platform that consolidates
molecular and immunoassay techniques in a single device. The first clinical
applications will be directed at infectious disease detection, antibiotic
resistance determination and detection of biomarkers in critically ill
patients.

"The Series B financing is a significant milestone that will support our
preparation for a European market launch in 2015," said Jordi Carrera, CEO and
co-founder of STAT-Diagnostica. "Our ability to close the round is proof of
the outstanding team behind the company, and demonstrates the potential of our
technology in the fast growing decentralized diagnostics market."

STAT-Diagnostica’s platform not only offers multi-analyte and multi-sample
capabilities, but it also reduces current diagnosis times (which can take up
to several days) by providing results in less than 30 minutes. The system’s
rapid performance will enable improved clinical decision making by medical
practitioners, delivering better patient management with direct and indirect
savings to the healthcare system.

"STAT-Diagnostica’s technological potential is evidenced by both its novel
diagnostic platform and the future diagnostic kits it will enable. In
addition, we have found the company to be led by a team with exceptional
competence, quality and professionalism," said Rémi Droller, managing partner,
Kurma Life Sciences Partners. "We have led this financing round with great
enthusiasm, and we share with all the investors the vision of transforming
STAT-Diagnostica into a reference company in the field of Near Patient Testing
diagnostics."

As part of the Series B financing, Ysios Capital significantly increased its
investment in STAT-Diagnostica to become the company’s largest shareholder.
Raúl Martín-Ruiz, investment director at Ysios Capital, commented on the
firm’s increased stake in the company. "When we invested in STAT-Diagnostica
in June 2011, the company was almost just an idea. Within two years,
STAT-Diagnostica has achieved pre-commercial validation of the technology,
which has reduced the technological risks significantly, and has successfully
raised the interest of specialized international investors. We are very
satisfied to have played a relevant role building up the investors syndicate."

Grant Thornton acted as financial advisor for the new investors and
Cuatrecasas as legal advisor. Rousaud Costas Duran acted as legal advisor for
the company.

About Kurma Life Sciences Partners

Founded in 2009 and based in Paris, Kurma Life Science Partners is a venture
capital firm with more than 135 million Euros under management. KLS Partners
is supported by two long-term investors: Natixis part of Group BPCE, the
second largest French bank; and state-owned Caisse des Depots et
Consignations. Kurma is active in the complete biotech value chain, from
technology transfer to more mature companies. KLS Partners has developed
access to investment opportunities through a network of privileged
partnerships in France and abroad, including the Institut Pasteur, Institut
Curie (France), the Imperial College, University College London (UK),
Karolinska Development (Sweden), and the VIB (Belgium).

About Ysios Capital

Ysios Capital is an independent venture capital firm providing private equity
financing to early- and mid-stage human healthcare and biotechnology companies
with special focus on pharmaceuticals, diagnostics and medical devices.
Founded in 2008, Ysios Capital manages Ysios BioFund I with 69 million Euros
and a portfolio target of 10 to 12 companies. Ysios’ investments to date
include: Inbiomotion (Barcelona), Medlumics (Madrid), AM-Pharma BV (Bunnik,
Netherlands), STAT Diagnostica (Barcelona), Sabirmedical (Barcelona), Cardoz
(Stockholm), Endosense (Geneva), BioVex (now Amgen, Boston) and Cellerix
(Madrid, now NYSE Alternext Tigenix NV: TIG).

About Idinvest Funds

With more than 3.5 billion Euros under management, Idinvest Partners is a
leading pan-European private equity management firm focused on the low and
middle market segments. The company has developed several complementary areas
of expertise, including investments in young innovative European companies;
primary, secondary and mezzanine investments in European non-listed companies;
and private equity consulting. Formerly part of the Allianz Group, the firm
was founded in 1997 and gained its independence in May 2010 with support from
the IDI Group.

About Boehringer Ingelheim Venture Fund

The Boehringer Ingelheim Venture Fund was formed in March 2010 to invest in
biotechnology and start-up companies to help drive innovation in medical
science. These may include – but are not limited to – novel technologies to
address targets not treatable with pharmaceutical drugs; next generation
vaccines; and new biological entities, such as antibody-dependent oncolysis.
Novel therapeutic targets, disease-related biomarkers, personalized medicine,
and new approaches in regenerative medicine are an additional focus.

About Caixa Capital Risc

Caixa Capital Risc is an institutional investor specialized in innovative,
early-stage Spanish companies with high growth potential, supporting them in
its various stages of development. Caixa Capital Risc manages four investment
funds with a total capital commitment of 73 million Euros. Caixa Capital
BioMed, endowed with 22 million Euros, invests in early-stage biotechnology
and medical technology companies and has a portfolio of 11 invested companies,
among which are nLife Therapeutics, Sanifit Laboratories, Sabirmedical,
Sagetis Biotech, Genmedica Therapeutics and Medlumics.

About Axis

Axis is the oldest venture capital firm in Spain and is wholly owned by
Instituto de Crédito Oficial. Since its creation in 1986, Axis has invested
nearly 300 million Euros in the growth of approximately 140 companies and
other venture capital funds. The fund Fond-ICOpyme, under Axis´s management,
is one of the most important growth funds in the Spanish market.

About STAT-Diagnostica

Founded in 2010 in Barcelona, STAT-Diagnostica is focused on the development
of Near Patient Testing solutions where fast and accurate diagnostic results
are needed. Its in vitro diagnostic system is a versatile, easy-to-use
platform that consolidates molecular and immunoassay techniques in a single
device.

Contact:

STAT-DIAGNOSTICA MEDIA CONTACT/U.S.:
Nobles Global Communications
Laura Nobles, 310-795-0497
laura@noblesgc.com
or
STAT-DIAGNOSTICA MEDIA CONTACT/EUROPE:
Genevensis Communications
Danièle Castle, +41 79 202 6667
info@genevensis.com